Niremia Collective

What Niremia Collective does

Niremia Collective is a Silicon Valley-based early-stage venture capital firm that operates a US-Japan bridge investing in wellbeing technology startups. The firm closed Fund I at $22.5 million in February 2024 and has assembled a portfolio of approximately twelve companies spanning consumer wellbeing, digital therapeutics, sleep tech, mental health, longevity, microbiome science, VR/XR immersion, and AI-enabled health platforms. Notable portfolio companies include Feno (smart oral care), TRIPP (VR wellness), DeepWell (therapeutic gaming), Medmain (AI pathology), Holobiome (microbiome therapeutics), Awear (lifestyle wearables), WellSet (integrative care), and Ozlo (sleep technology).

The fund operates a thesis-driven model that blends consumer and clinical wellbeing verticals under a "TransformativeTech" framing, targeting the broader $8.5 trillion projected global wellness market by 2027. Distribution flows through the firm's TransformativeTech community, which has grown to approximately 9,000 members across 72 countries, functioning as both deal-sourcing and portfolio-support infrastructure. Limited partners include Shionogi Pharmaceuticals, Mistletoe Venture Partners (founded by Taizo Son), and MIXI Inc., providing both capital and strategic Japan-market access.

The firm is co-led by Naoko Okumoto (Managing Partner) and Nichol Bradford (Partner), with advisory involvement from Hiroaki Kitano (Sony Group CTO) and Rene Caissie (Medeloop.ai CEO). Okumoto previously drove US investments for Mistletoe, creating a direct relationship to one of the fund's LPs. Revenue mechanics follow the standard emerging-manager VC model: management fees on committed capital (typically approximately 2% annually on the $22.5M fund), with potential carried interest on realized gains as the portfolio matures; no Fund II has been disclosed at this time.

Name

Niremia Collective

Legal name

Niremia Collective

Website

https://niremia.vc

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Niremia Collective is a Silicon Valley-based early-stage venture capital firm operating a US-Japan bridge that invests in wellbeing technology startups through its $22.5M Fund I, with portfolio companies spanning VR wellness, AI health, microbiome therapeutics, and digital sleep.

Ownership category

akta.pro rank

Product category

Venture Capital / Wellbeing Tech Investments

NAICS

Open-End Investment Funds (525910)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Wellbeing technology investing
• Early-stage venture capital
• Health tech fund
• Digital health investments
• Mental wellness startups

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Venture Capital Fund Management: Niremia Collective generates returns through capital appreciation of portfolio companies. Fund I ('Niremia Collective Fund I, LP') was closed at $22.5 million with limited partners including Shionogi Pharmaceuticals, Mistletoe Venture Partners, and MIXI Inc. Revenue comes from management fees and carried interest from successful portfolio exits.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Niremia Collective is a Silicon Valley-based early-stage venture capital firm that deploys capital into wellbeing technology startups. It operates its debut fund, Niremia Collective Fund I, LP ($22.5M), investing in companies developing mental, emotional, and social health (MESH) solutions, digital therapeutics, AI/VR wellness platforms, microbiome science, and longevity technologies. The firm provides capital plus management resources and ecosystem access through its partnership with TransformativeTech.

Product overview

Niremia Collective is a Silicon Valley-based venture capital firm that operates as a single investment fund vehicle (Niremia Collective Fund I, LP), targeting the $8.5 trillion wellness and wellbeing market by 2027. Rather than developing a unified software product, the firm provides capital and management resources to early-stage well-being technology startups through its portfolio of approximately 12 companies. The portfolio spans digital health platforms, AI-powered wellness devices, VR/AR therapy, microbiome therapeutics, and workplace wellness solutions, unified by Niremia's focus on mental, emotional, and social health (MESH).

Differentiator

Problem solved

Functional benefit

Products and services

• Niremia Collective Fund I, LP Niremia Collective's inaugural venture capital fund focused on well-being technology startups. The $22.5 million fund targets early-stage companies in mental, emotional, and social health (MESH), new ways of working, healthy aging, human-centric urban design, food technology, living environment technologies, and women's health. Provides LPs with exposure to a portfolio of twelve startups and access to the TransformativeTech ecosystem.

Quantifiable outcome

• Wellness market projected to reach $8.5 trillion globally by 2027
• +2 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and major.

• TransformativeTechcoreStrategic or Co-development PartnerFounded by Nichol Bradford in 2014, TransformativeTech is the world's largest wellbeing tech ecosystem with approximately 9,000 members across 72 countries. Niremia leverages this network for deal flow, insights, and ecosystem support. The network includes startups, investors, universities, research institutions, and corporations.
• Johnson & Johnson Consumer Inc.majorStrategic or Co-development PartnerHolobiome (portfolio company) announced research collaboration with Johnson & Johnson Consumer Inc. to develop next-generation probiotics and prebiotics aimed at supporting infant and maternal immune health.
• UnilevermajorStrategic or Co-development PartnerHolobiome (portfolio company) partnered with global consumer goods company Unilever to identify food and beverage ingredients that aid in stress management, building on insights into gut bacteria that produce GABA (a neurotransmitter essential for regulating mood and anxiety).

Scale indicators4 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Mindset Ventures: Early-stage venture firm focused exclusively on wellbeing, mental health, and longevity technologies. Directly comparable to Niremia in vertical specialization, deal stage (pre-seed/seed), and category thesis around human potential and flourishing.
• Obvious Ventures: Mission-driven VC firm investing in companies addressing planetary health, human health, and economic health. Comparable to Niremia through shared focus on health/wellbeing thesis, early-stage investing, and values-aligned capital approach.
• StartUp Health: Health transformation company that operates a collaborative venture fund and global community of health innovators. Directly comparable via dedicated health/wellbeing vertical focus, network-driven deal flow, and mission to fund moonshot health startups.

Broad incumbents

• General Catalyst: Multi-stage venture firm with a dedicated Health Assurance and health-tech practice. Comparable to Niremia in health/wellbeing investing but operates at much larger scale across broader sectors.
• Khosla Ventures: Large venture firm with significant exposure to health, wellness, and frontier-tech startups. Comparable as a sector-focused investor but at far greater scale than Niremia.
• Andreessen Horowitz (a16z Bio + Health): Major venture firm operating a dedicated Bio + Health fund targeting digital health, biotech, and wellness categories. Overlaps with Niremia's health/wellbeing thesis at a much broader portfolio scale.
• ARCH Venture Partners: Long-established venture firm focused on early-stage life sciences and health-tech companies. Comparable through deep-health investing focus and early-stage orientation.
• Lux Capital: Frontier-tech venture firm with significant health-tech, neurotech, and bio portfolio exposure. Comparable through investments in neuroscience, digital health, and futuristic wellbeing technologies (similar to Niremia's TRIPP/Awear bets).
• Norwest Venture Partners: Multi-stage venture firm with a long-standing healthcare and wellness investment practice. Comparable to Niremia through dedicated health portfolio and willingness to back early-stage health-tech companies.
• Founders Fund: Major venture firm investing across frontier technology, including health and biotech. Comparable to Niremia through bold-thesis, early-stage approach but operating at far greater scale across broader categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/niremia-collective
• Instagraminstagram.com/wix

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Niremia Collective